Uveal melanoma guidelines

Uveal (ocular) melanoma is a very rare form of the disease, which is managed differently from other melanomas. Comprehensive guidance on this subject was developed for the first time in 2015. This guideline was developed by a leading clinical and research specialist interdisciplinary group with patient input. While much of the guideline is still current, the 2022 guidelines updated the following sections:

  • molecular pathology and features
  • prognostic markers
  • loco-regional management of hepatic predominant disease
  • management of metastatic disease
  • adjuvant radiation therapy
  • support of patients

Uveal (ocular) melanoma is a very rare form of the disease, it requires different clinical management from other melanomas

Uveal Melanoma Guidelines

We are extremely grateful to Dr Paul Nathan, Trustee (consultant medical oncologist, Mount Vernon Cancer Centre) for chairing the guidelines development group (GDG) which formed in 2020 to review the 2015 guidelines. The group from fields of medical oncology, clinical oncology, radiology, pathology, uveal melanoma science and patient representation with project management and methodological support provided by Mrs Nancy Turnbull, the Project Manager.

Follow the individual links below for the relevant guidelines:

Following the completion of the Uveal melanoma guidelines, Dr Paul Nathan stated:

“The Uveal Melanoma National Guidelines have recommended standards of care for all of our patients across the UK. These updated guidelines include recent advances in our understanding of the distinct biology of this disease, assess the evidence for recent improvements in care and have a renewed focus on patient experience. We believe they will continue to be an important reference document for patients, their supporters and clinicians.  I would like to particularly thank Nancy Turnbull for facilitating the process and my colleagues on the guidelines committee who have given so much of their time and expertise to this worthwhile effort. Furthermore, these updated guidelines wouldn’t have materialised without the funding from Melanoma Focus who received a welcome donation from OcuMel UK”.

Update of Metastatic Surveillance of Uveal Melanoma – Invitation for Expressions of Interest

Melanoma Focus has begun preparatory work to set up a Guideline Development Group (GDG) to update metastatic surveillance of Uveal Melanoma (UM) guideline which was originally published in 2015.

We are therefore putting together a group to undertake this work.

The Guideline Development Group (GDG) will be led by Dr Matthew Wheater, with project management and methodological support and funding by Melanoma Focus.

We are therefore looking for the following:

  • Ophthalmologist who treats uveal melanoma
  • Medical oncologists with an interest in melanoma
  • Pathologist with an interest in melanoma
  • Radiologist with an interest in melanoma and modality used for surveillance
  • Liver surgeon with an interest in metastatic melanoma
  • Patient representatives ideally one representative who has been recently diagnosed and one who has had UM for several years

For more information and to get involved, please click here.

COPYRIGHT NOTICE: ALL documents are Copyright © 2018 & 2020 Melanoma Focus. Permission is granted to reproduce them, with attribution to Melanoma Focus, for personal clinical and educational use only. Commercial copying or lending is prohibited.

Further resources

Nathan P, et al. Uveal Melanoma Guideline Development Working Group. Uveal Melanoma UK National Guidelines. Eur J Cancer. 2015 Nov;51(16):2404-12. doi: 10.1016/j.ejca.2015.07.013. Epub 2015 Aug 13. PMID: 26278648.
The full text PDF publication is available to download here

NB: These Guidelines were developed in accordance with the Melanoma Focus Guideline Development Methodology Manual. The methods have been accredited by NICE as complying with their AGREE II criteria for the rigorous development of evidence-based guidelines.
Nice accredited logo